Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036. [electronic resource]
- Cancer letters Oct 2011
- 110-8 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1872-7980
10.1016/j.canlet.2011.05.023 doi
Antineoplastic Agents--pharmacology Cell Line, Tumor DNA Breaks, Double-Stranded DNA Repair--genetics Drug Resistance, Neoplasm--genetics Female Humans Organoselenium Compounds--pharmacology Pyrroles--pharmacology Up-Regulation Uterine Cervical Neoplasms--drug therapy